Helping Patients Since 2009
AFINITOR has delivered efficacy and safety data backed by more than a decade of clinical use.1 First approved by the FDA in 2009,1 the figures speak for themselves:
– Over 7501 published articles2
– Over 1257 clinical trials3
– Over 1.1 million packs distributed4
Novartis supports patients through access to a variety of financial, counseling, and co-pay programs.
Patient Support and Co-Pay Program
Novartis is proud to support patients through various financial, counseling, and co-pay programs.
Novartis Oncology Universal Co-Pay Program
Patients may be eligible for immediate co-pay savings on their next prescription of AFINITOR® (everolimus) Tablets and AFINITOR DISPERZ® (everolimus tablets for oral suspension).
Eligible patients with private insurance may pay $0 per month
Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*
Encourage your patients to find out if they are eligible to enroll in the Novartis Oncology Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.
Patient Assistance Now Oncology
Patient Assistance Now Oncology (PANO) is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient Support services. Dedicated support specialists help direct callers to the services that best fit their needs.
Learn more by visiting HCP.Novartis.com/Access or calling 1-800-282-7630